The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks again Soup, it's nice to start the week with a little more optimism after all the ****e we've endured over the last 12 months.
Fingers crossed
Good work, this agreement and upfront payment could be the catalyst needed. Would love an end tomorrow, the wait for the update makes sense if this is a go
Why wouldn't we be going with what we have ?
what we need to be told -are we going with what we have or going back to the drawing board.
a new drug will want funds ,existing i think we can survive,
the update very much should give be explicit.
we need the truth after losing the market with fairy tales.
Interesting that Oxilio has a MoU with Biocopea which is a wholly owned subsidiary of Seek. Seek has a vertically integrated cannabis subsidiary called Provenance. As already mentioned Biocopea had a contract relationship with Sosei.
Looks like great news it would have to be Oxillo’s focus given they had a 6 months license limit. RNS is interesting;
“ in return for a significant upfront payment and additional development milestones and a royalty on net sales, capped at £2 million per annum”
One could argue the cap was disappointing but NFX total operating costs for 2020 was £1.5m so totally underwritten. The upfront payment could double the company NAV.
Thanks for posting Soup. Just had a look at the Oxilio website. Looks promising...
Hopefully any future upfront fee is advertised in the RNS with our new CEO looking to win over shareholders.
There were too many games being played with regards to Ebers, Vistagen and Oxillo, when they chose not to disclose any figures. We need transparency after losing so much sentiment over the last year.
Every egg a bird
Yes. His LinkedIn page states he worked at Sosei. Looks like he stayed on after the takeover of Arakis.
Interesting that Oxilio also have an MoU with Biocopea.
Biocopea was founded by a Dr Roger Bannister (not the runner) who previously co-founded Arakis with NFX director Julian Gilbert.
Sorry Kane, no Kate, fat fingers and android phones ??
Agreed, thanks to both Soup and Kate.
Oxilio does sound hopeful for NXP001 (even the name OXL001 seems to pay homage)
A 2m royalty cap might end up being a little on the low side if Oxilio do succeed.
Some great finds this afternoon. Thank you Soupdragon and Kane.
Not sure if this has been shared it’s from 7th January it’s a news article and it says nuformix and ebers are still working together to to make cannabinoid cocrystals!! It won’t let me copy and paste but here’s the link
https://www.pressreader.com/canada/stockwatch-daily/20210108/282252373160406
Option expires end of March, hence fund raising during / closing in March prior to outlicensing within the timeframe.
All the signs add up for Oxilio gearing up through a funding to pay for taking NXP001 into clinical trials this year for oncology.
Oxilio option on NXP001 expires in March.
Oxilio will be undertaking an open funding in the next month, value of them at £20m
“ March 2021 open funding round - £20.3m pre money valuation”
https://www.oxilio.co.uk/investors
Could this be based on NXP001?
Our OXL001 clinical trial programme is being designed to satisfy all aspects of drug safety and efficacy associated with optimal formulation, dose and dosing regimen of OXL001 in the treatment of cancer. The programme is informed by our advanced formulation and modelling/simulation work.
We aim to take our first formulation of OXL001 into the clinic later in 2021.
Could we be about to see something start to move here.
Oxilio website went live today.
https://www.oxilio.co.uk/